Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

A report from Ozmosi estimates that seven new GLP-1 agonists could launch in the U.S. by 2030. Competition isn't ideal for Eli Lilly ... company dedicated to building the world's greatest ...

Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor ...

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is ...

Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across therapeutic areas by building four new ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing ... with another 500 positions required while it is under construction. The plans are due to be submitted ...

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal ...

The announcement comes as drugmakers unveil investments to deal with tariffs from the Trump administration, which is seeking to boost domestic manufacturing ...

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

Eli Lilly has raised its ... Rocks stressed, however, that Lilly's primary production strategy is "self-run sites." He said: "We're quite comfortable building operating sites, and as the newest ...